- Home
- ANAB vs TRNZ Comparison
ANAB vs TRNZ Comparison
Compare ANAB & TRNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANAB | TRNZ |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ANAB | TRNZ |
|---|---|---|
| Price | $48.43 | $25.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $88.50 | N/A |
| AVG Volume (30 Days) | ★ 441.4K | 16.6K |
| Earning Date | 09-21-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ 0.85 |
| Revenue | ★ $234,603,000.00 | N/A |
| Revenue This Year | $17.97 | N/A |
| Revenue Next Year | $36.88 | N/A |
| P/E Ratio | ★ N/A | $29.42 |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $29.49 | $24.47 |
| 52 Week High | $73.30 | $25.50 |
Technical Indicators
Market Signals| Indicator | ANAB | TRNZ |
|---|---|---|
| Relative Strength Index (RSI) | 33.62 | 35.73 |
| Support Level | $49.93 | $24.99 |
| Resistance Level | $51.67 | $25.14 |
| Average True Range (ATR) | 2.07 | 0.07 |
| MACD | -0.37 | -0.01 |
| Stochastic Oscillator | 13.66 | 12.38 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).